Showing results (1551-1560 of 1,599) with videos related to

Sort By:
Pageof 160
Leukemia|July 25, 2019
Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemiaHuafeng Wang, Dandan Zhao, Le Xuan Nguyen, et al.
Medrxiv : the Preprint Server for Health Sciences|April 16, 2025
Designing an Electronic Patient Reported Outcomes Information Infrastructure Supported by the RE-AIM Implementation FrameworkAmy C Moreno, Angela Peek, Toshiko S Stein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2012
Cancer- and chemotherapy-induced anemiaGeorge M Rodgers, Pamela Sue Becker, Morey Blinder, et al.
The Journal of Biological Chemistry|October 2, 2015
Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2Amel Dudakovic, Emily T Camilleri, Fuhua Xu, et al.
Journal of Cellular Physiology|May 16, 2017
Intranuclear and higher-order chromatin organization of the major histone gene cluster in breast cancerAndrew J Fritz, Prachi N Ghule, Joseph R Boyd, et al.
Nature|January 26, 2007
Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2Daniel W Young, Mohammad Q Hassan, Jitesh Pratap, et al.
Journal of Cellular Physiology|March 27, 2015
The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell ProliferationQiong Wu, Pasil Madany, Jacqueline Akech, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 15, 2025
Retreatment of Hepatitis C Virus Among People Who Inject DrugsAurielle M Thomas, Alain H Litwin, Judith I Tsui, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 26, 1999
Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survivalM Ross, G M Schmidt, J C Niland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancerA D Seidman, A Brufsky, R H Ansari, et al.
Pageof 160